Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health problems news

Show

From To
Individualized lifestyle intervention may reduce type 2 diabetes risk in HIV

For adults with HIV, a lifestyle intervention focused on energy restriction, weight reduction and improved diet may be an effective way to decrease type 2 diabetes risk, according to findings published in Diabetic Medicine.

Published
14 March 2019
From
Healio
TB CAB statement on safety of using bedaquiline and delamanid together

he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

Published
14 March 2019
From
TB Online
Large French study examines neuropsychiatric side effects with integrase inhibitors

The largest prospective study to date on integrase inhibitors and their potential for being associated with neuropsychiatric side effects was conducted in France. With more than 21,000 HIV-positive participants, the study found that the proportion of people who stopped taking integrase inhibitors due to neuropsychiatric side effects was generally very low (between 1% and 3%). Of particular note is the fact that before starting treatment with an integrase-inhibitor-containing regimen, between 3% and 10% of participants had previously reported neuropsychiatric side effects with other classes of HIV treatment.

Published
12 March 2019
From
CATIE
'Patient No. 1' from a Hep C heart transplant study shares his story

By the time three transplant physicians approached Tom Giangiulio Jr. about being the first patient in a new clinical trial to accept a heart from a Hepatitis C-positive donor, Giangiulio didn’t have much of a choice.

Published
08 March 2019
From
Cardiovascular Business
Experts tackle major cardiovascular issues in treating patients with HIV

Since the advent of effective antiretroviral therapy (ART), HIV infection has become more like a chronic illness. Now that patients are able to live longer and remain free of developing AIDS, they have begun to encounter new risks from age-related disorders common in the general population, including cardiovascular disease (CVD).

Published
05 March 2019
From
EurekAlert!
Ireland: The new HIV crisis needs a better response

HIV is a public heath issue, but a spike in diagnoses in Ireland seems to be going unchecked. New figures published last week show there were 531 new cases of HIV infections diagnosed in 2018, an increase from 492 in 2017. There is now a new diagnosis of HIV in Ireland every 17 hours; Ireland’s rate of new diagnoses stood at 10.2 per 100,000 people in 2017, while the European average is 6.2 per 100,000.

Published
04 March 2019
From
Irish Times
What are the treatment challenges for the over 50s in Africa?

Although older adults in Uganda showed a high regard for the importance of anti-retroviral treatment, structural factors such as wait times and ageism still provide barriers to adherence.

Published
28 February 2019
From
AVERT
HIV status does not preclude receipt of curative cervical cancer therapy in Botswana

Women in Botswana with well-managed HIV had the same access to curative chemoradiotherapy for cervical cancer as women without HIV, according to results of an observational study published Cancer.

Published
27 February 2019
From
Healio
Switching to Raltegravir or Dolutegravir Improves Leptin and Insulin in HIV

Switching to either raltegravir or dolutegravir from a ritonavir-boosted protease inhibitor during combination antiretroviral therapy (ART) has been associated with improved serum leptin levels and homeostasis model assessment of insulin resistance (HOMA) index scores in people with HIV infection, according to a study recently published in the Journal of Antimicrobial Chemotherapy.

Published
27 February 2019
From
Infectious Disease Advisor
Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV

Gilead Sciences, Inc. today announced it is providing $17.6 million in grants to 30 organizations in the United States through the Gilead HIV Age Positively initiative. This effort aims to enhance the lives of individuals aging with HIV by focusing in three priority areas: improving care coordination, increasing resources for better well-being, and educating and informing policies that impact people living and aging with HIV.

Published
27 February 2019
From
Gilead press release
← First12345...120Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.